A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infectio... by Sklar, MJ, Maiolatesi, S, Patterson, N, Berrie, E, Bellamy, D, Bittaye, M, Ewer, K, Lawrie, A, Hill, A

A Phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS by De Barra, E, Hodgson, S, Ewer, K, Bliss, C, Hennigan, K, Collins, A, Berrie, E, Lawrie, A, Gilbert, S, Nicosia, A, McConkey, S, Hill, A

Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. by Glatting, G, Müller, M, Koop, B, Hohl, K, Friesen, C, Neumaier, B, Berrie, E, Bird, P, Hale, G, Blumstein, N, Waldmann, H, Bunjes, D, Reske, SN

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine by Folegatti, P, Bellamy, D, Roberts, R, Powlson, J, Edwards, N, Mair, C, Bowyer, G, Poulton, I, Mitton, C, Green, N, Berrie, E, Lawrie, A, Hill, A, Ewer, K, Hermon-Taylor, J, Gilbert, S

CLINICAL EVALUATION OF NEW VIRAL VECTORED VACCINES TARGETING THE PLASMODIUM FALCIPARUM BLOOD-STAGE ANTIGENS; MSP1 AND AMA1 by Sheehy, S, Duncan, C, Anagnostou, N, Elias, S, Halstead, F, Collins, K, Ewer, K, Edwards, N, Douglas, A, Gantlett, K, Lawrie, A, Berrie, E, Moyles, S, Long, C, Sinden, R, Blagborough, A, Murphy, J, Nicosia, A, Hill, A, Draper, S

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1 by Borthwick, N, Ahmed, T, Ondondo, B, Hayes, P, Rose, A, Ebrahimsa, U, Hayton, E, Black, A, Bridgeman, A, Rosario, M, Hill, A, Berrie, E, Moyle, S, Frahm, N, Cox, J, Colloca, S, Nicosia, A, Gilmour, J, Mcmichael, A, Dorrell, L, Hanke, T

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial. by Hodgson, S, Choudhary, P, Elias, S, Milne, K, Rampling, T, Biswas, S, Poulton, I, Miura, K, Douglas, A, Alanine, D, Illingworth, J, de Cassan, S, Zhu, D, Nicosia, A, Long, C, Moyle, S, Berrie, E, Lawrie, A, Wu, Y, Ellis, R, Hill, A, Draper, S

Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. by Borthwick, N, Ahmed, T, Ondondo, B, Hayes, P, Rose, A, Ebrahimsa, U, Hayton, E, Black, A, Bridgeman, A, Rosario, M, Hill, A, Berrie, E, Moyle, S, Frahm, N, Cox, J, Colloca, S, Nicosia, A, Gilmour, J, McMichael, A, Dorrell, L, Hanke, T

Safety and immunogenicity of a replication deficient simian adenoviral vectored chikungunya vaccine: A phase I, first-in-human, dose escalation trial by Folegatti, PM, Harrison, K, Lopez, KR, Tilley, MW, Lopez-Camacho, C, Kim, YC, Preciado-Llanes, L, Rossi, SL, Poulton, I, Jenkin, D, Datoo, M, Themistocleous, Y, Lawrie, A, Roberts, R, Ewer, K, Berrie, E, Hill, A, Reyes-Sandoval, A

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial by Payne, R, Silk, S, Elias, S, Miura, K, Diouf, A, Alanine, D, Jin, J, Labbe, G, Brian, I, Poulton, I, Griffiths, O, Edwards, N, Berrie, E, Siani, L, Douglas, A, Roberts, R, Vekemans, J, Nugent, F, Hill, A, Long, C, Lawrie, A, Draper, S

Phase Ia clinical evaluation of the plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors by Sheehy, S, Duncan, C, Elias, S, Collins, K, Ewer, K, Spencer, A, Williams, A, Halstead, F, Moretz, SE, Miura, K, Epp, C, Dicks, M, Poulton, I, Lawrie, A, Berrie, E, Moyle, S, Long, C, Colloca, S, Cortese, R, Gilbert, S, Nicosia, A, Hill, A, Draper, S

ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans by Sheehy, S, Duncan, C, Elias, S, Choudhary, P, Biswas, S, Halstead, F, Collins, K, Edwards, N, Douglas, A, Anagnostou, N, Ewer, K, Havelock, T, Havelock, T, Mahungu, T, Bliss, C, Miura, K, Poulton, I, Lillie, P, Antrobus, R, Berrie, E, Moyle, S, Gantlett, K, Colloca, S, Colloca, S, Cortese, R

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. by Sheehy, S, Duncan, C, Elias, S, Collins, K, Ewer, K, Spencer, A, Williams, A, Halstead, F, Moretz, SE, Miura, K, Epp, C, Dicks, MD, Poulton, I, Lawrie, A, Berrie, E, Moyle, S, Long, C, Colloca, S, Cortese, R, Gilbert, S, Nicosia, A, Hill, A, Draper, S

A single dose of ChAdOx1 Chik vaccine induces neutralising antibodies against four chikungunya virus lineages in a phase 1 clinical trial by Folegatti, P, Harrison, K, Preciado-Llanes, L, Ramos Lopez, F, Bittaye, M, Kim, Y, Flaxman, A, Bellamy, D, Makinson, R, Sheridan, J, Tilley, M, Tran, N, Jenkin, D, Poulton, I, Lawrie, A, Roberts, R, Berrie, E, Hill, A, Ewer, K, Reyes-Sandoval, A

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. by Sheehy, S, Duncan, C, Elias, S, Choudhary, P, Biswas, S, Halstead, F, Collins, K, Edwards, N, Douglas, A, Anagnostou, N, Ewer, K, Havelock, T, Mahungu, T, Bliss, C, Miura, K, Poulton, I, Lillie, P, Antrobus, R, Berrie, E, Moyle, S, Gantlett, K, Colloca, S, Cortese, R, Long, C, Sinden, R

Prime and target immunization protects against liver-stage malaria in mice by Gola, A, Silman, D, Walters, A, Uderhardt, S, Salman, A, Halbroth, B, Bellamy, D, Bowyer, G, Powlson, J, Baker, M, Venkatraman, N, Poulton, I, Berrie, E, Roberts, R, Lawrie, A, Angus, B, Khan, S, Janse, C, Ewer, K, Germain, R, Spencer, A, Hill, A

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 t... by Folegatti, PM, Bittaye, M, Flaxman, A, Ramos Lopez, F, Bellamy, D, Mair, C, Makinson, R, Sheridan, J, Boyd, A, Tran, N, Silman, D, Poulton, I, Datoo, M, Marshall, J, Themistocleous, Y, Lawrie, A, Roberts, R, Berrie, E, Lambe, T, Hill, A, Ewer, K, Gilbert, S, Et al.

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. by Sheehy, S, Duncan, C, Elias, S, Biswas, S, Collins, K, O'Hara, G, Halstead, F, Ewer, K, Mahungu, T, Spencer, A, Miura, K, Poulton, I, Dicks, M, Edwards, N, Berrie, E, Moyle, S, Colloca, S, Cortese, R, Gantlett, K, Long, C, Lawrie, A, Gilbert, S, Doherty, T, Nicosia, A, Hill, A, Draper, S

New vectored vaccines for malaria. by Hill, A, Reyes-Sandoval, A, Draper, S, O'Hara, G, Spencer, A, Cottingham, M, Sridhar, S, Moore, A, Goodman, A, Larsen, K, Saurya, S, Calvert, A, Furze, J, Biswas, S, Forbes, E, Berrie, E, Bird, P, Bregu, M, Rollier, C, Lawrie, A, Rowland, R, Ertl, H, Nicosia, A, Siani, L, Colloca, S

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations. by Kimani, D, Jagne, Y, Cox, M, Kimani, E, Bliss, C, Gitau, E, Ogwang, C, Afolabi, M, Bowyer, G, Collins, K, Edwards, N, Hodgson, S, Duncan, C, Spencer, A, Knight, MG, Drammeh, A, Anagnostou, N, Berrie, E, Moyle, S, Gilbert, S, Soipei, P, Okebe, J, Colloca, S, Cortese, R, Viebig, N